People in treatment for major depression now have another recovery option to try. Rejoyn, the first-ever app cleared by the Food and Drug Administration to help treat depression, officially launched ...

Last month, an app named Rejoyn became the first FDA-cleared prescription digital therapeutic for patients with major depressive disorder. The app, which changes users’ behavior through various ...

The landscape of mental health care is undergoing a significant transformation. Traditional methods of treatment, while valuable, may fall short for some and leave those patients looking for more ...

The app-based treatment for major depression disorder has received FDA clearance. Here's what to know before it's available this summer. Taylor Leamey wrote about all things wellness for CNET, ...

The US Food and Drug Administration is allowing the use of Rejoyn, the first prescription digital treatment for major depressive disorder. Rejoyn, made by Otsuka Pharmaceutical and Click Therapeutics, ...

Rejoyn is a medical device designed as a phone app that targets major depressive disorder. Photo by NordWood Themes on Unsplash The U.S. Food and Drug Administration (FDA) is allowing the use of ...

Credit: Otsuka. At this time, the product is available to patients for a discounted price of $50; the full price is $200. Rejoyn ™, the first prescription digital therapeutic cleared for the treatment ...

Otsuka Pharmaceutical has started selling Rejoyn, its Food and Drug Administration cleared prescription app that treats the symptoms of major depressive disorder. And it’s hitting the market at a low ...

Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration (FDA) is allowing the use of mobile app Rejoyn to be the first prescription digital ...